SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · Rhythm Pharmaceuticals reported Q3 2026 IMCIVREE revenue of $92.1M, a…

Rhythm Pharmaceuticals, Inc. · PRESS-RELEASE filed Nov 3, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Nov 3, 2026 at 07:00 ET

Rhythm Pharmaceuticals reported Q3 2026 IMCIVREE revenue of $92.1M, a 29% sequential increase and 80% YoY growth, beating the $84.6M consensus. Net loss per share of $(0.61) was narrower than the consensus estimate of $(0.74). The company also secured a $750M term loan facility and amended its bivamelagon license with LG Chem, reducing the royalty to 1% in exchange for $350M in fixed payments.

  • Q3 2026 IMCIVREE net product revenue of $92.1M, up 29% sequentially and 80% YoY from $51.3M
  • Revenue beat consensus of $84.6M by 8.9%
  • GAAP net loss per share of $(0.61) vs consensus estimate of $(0.74)
  • Over 700 patient start forms for IMCIVREE in acquired HO from more than 500 prescribers as of Sep 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access